Repligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device
02 Novembre 2023 - 12:30PM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced the
commercial launch of TangenX® SC, the industry’s first holder-free,
self-contained Tangential Flow Filtration (TFF) device. The
technology is especially suited to the manufacture of biologics
where fully closed systems are critical or ideal, including
antibody drug conjugates (ADCs), viral vectors, nucleic acids and
lipid nanoparticles, and can also be applied to monoclonal
antibody, and recombinant protein production. TangenX SC is not
only transformative, it is also a milestone achievement in the
advancement of downstream flat sheet TFF technology for
ultrafiltration and diafiltration (UF/DF), which is performed in
nearly every biopharmaceutical manufacturing process to concentrate
and purify drug.
Christine Gebski, Senior Vice President, Filtration and
Chromatography at Repligen, said, “TangenX SC pushes the boundaries
of TFF innovation, offering clear advantages to virtually any user
of flat sheet TFF. The holder-free TangenX SC device simplifies and
streamlines downstream flat sheet UF/DF processes like never
before. Users can trust that the quality and consistency of their
TFF processes remain uncompromised while enjoying the benefits of
this innovative technology.”
Compared with traditional flat sheet TFF cassettes,
“plug-and-play” TangenX SC self-contained devices offer several key
advantages that drive significant efficiency and productivity
gains:
- Significant time savingsTangenX SC’s
holder-free design and simplified assembly is demonstrated to
reduce set up time by 80%.
- Reduced risk of product lossThe novel
self-contained device eliminates holders and torquing requirements,
reducing the risk of product loss caused by changes in compression
or cassette misalignment during installation.
- ScalabilityTangenX SC devices scale from pilot
to process scale. Designed with the same flow path length and
channel geometry as traditional cassettes, TangenX SC allows users
to seamlessly transition from traditional cassettes.
- Single-use, gamma sterilizedTangenX SC devices
are aseptically closed and gamma irradiated to reduce bioburden
risk and permit use in Controlled not Classified (CNC)
manufacturing environments. The closed design also enhances safety
by isolating operators from potentially hazardous materials.
This next-generation technology provides Repligen’s
biopharmaceutical manufacturing customers with an expanded
selection of flat sheet TFF offerings, beyond its TangenX SIUS® and
SIUS Gamma single-use cassettes and PRO reusable cassettes.
About Repligen CorporationRepligen Corporation
is a global life sciences company that develops and commercializes
highly innovative bioprocessing technologies and systems that
enable efficiencies in the process of manufacturing biological
drugs. We are “inspiring advances in bioprocessing” for the
customers we serve; primarily biopharmaceutical drug developers and
contract development and manufacturing organizations (CDMOs)
worldwide. Our focus areas are Filtration and Fluid Management,
Chromatography, Process Analytics and Proteins. Our corporate
headquarters are located in Waltham, Massachusetts, and the
majority of our manufacturing sites are in the U.S., with
additional key sites in Estonia, France, Germany, Ireland, the
Netherlands and Sweden. For more information, please visit
www.repligen.com, and follow us on LinkedIn.
Forward-Looking StatementsThis press release
may contain forward-looking statements within the meaning of the
federal securities laws. Investors are cautioned that statements in
this press release which are not strictly historical statements
including, without limitation, statements identified by words like
“believe,” “expect,” “may,” “will,” “should,” “seek,” or “could”
and similar expressions, constitute forward-looking statements.
Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those anticipated, including risks discussed from
time to time in our filings with the Securities and Exchange
Commission. We expressly disclaim any responsibility to update any
forward-looking statements, except as required by law.
Contact:Sondra S. NewmanGlobal
Head of Investor Relationsinvestors@repligen.com781-250-0111
Repligen (NASDAQ:RGEN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Repligen (NASDAQ:RGEN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024